• Western blot analysis of lysates from HUVEC, HepG2, and Jurkat cells, using NT Antibody. The lane on the right is blocked with the synthesized peptide.
  • Western blot analysis of the lysates from HepG2 cells using NT antibody.
  • Western blot analysis of various cells using Neurotrimin Polyclonal Antibody

Anti-NTM antibody (235-284) (STJ94442)

SKU:
STJ94442

Current Stock:
Host: Rabbit
Applications: WB/IHC/IF/ELISA
Reactivity: Human/Rat/Mouse
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-Neurotrimin (235-284) is suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence and ELISA research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-1:2000
IHC 1:100-1:300
ELISA 1:20000
IF 1:50-200
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: NTM
Gene ID: 50863
Uniprot ID: NTRI_HUMAN
Immunogen Region: 235-284
Specificity: Neurotrimin Polyclonal Antibody detects endogenous levels of Neurotrimin protein.
Immunogen: The antiserum was produced against synthesized peptide derived from human NT. AA range:235-284
Function Neural cell adhesion molecule.
Protein Name Neurotrimin
Hnt
Iglon Family Member 2
Database Links Reactome: R-HSA-163125
Cellular Localisation Cell Membrane
Lipid-Anchor
Gpi-Anchor
Alternative Antibody Names Anti-Neurotrimin antibody
Anti-Hnt antibody
Anti-Iglon Family Member 2 antibody
Anti-NTM antibody
Anti-IGLON2 antibody
Anti-NT antibody
Anti-UNQ297 antibody
Anti-PRO337 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance